Page last updated: 2024-10-31

metronidazole and Brain Injuries, Penetrating

metronidazole has been researched along with Brain Injuries, Penetrating in 1 studies

Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.

Research Excerpts

ExcerptRelevanceReference
"Infections from penetrating brain injuries (PBI) lead to higher morbidity and mortality rates."1.56Evaluation of prophylactic antibiotics in penetrating brain injuries at an academic level 1 trauma center. ( Adamski, J; Marut, D; McKenzie, C; Shammassian, B; Traeger, J, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Marut, D1
Shammassian, B1
McKenzie, C1
Adamski, J1
Traeger, J1

Other Studies

1 other study available for metronidazole and Brain Injuries, Penetrating

ArticleYear
Evaluation of prophylactic antibiotics in penetrating brain injuries at an academic level 1 trauma center.
    Clinical neurology and neurosurgery, 2020, Volume: 193

    Topics: Academic Medical Centers; Adolescent; Adult; Antibiotic Prophylaxis; Cefazolin; Ceftriaxone; Concurr

2020